An acute exposure to perfluorooctanoic acid causes non-reversible plasma membrane injury in HeLa cells.

Autor: Peropadre A; Department of Biology (Lab A-110), Faculty of Sciences, Universidad Autónoma de Madrid, C/Darwin 2, 28049, Madrid, Spain., Hazen MJ; Department of Biology (Lab A-110), Faculty of Sciences, Universidad Autónoma de Madrid, C/Darwin 2, 28049, Madrid, Spain., Pérez Martín JM; Department of Biology (Lab A-110), Faculty of Sciences, Universidad Autónoma de Madrid, C/Darwin 2, 28049, Madrid, Spain., Fernández Freire P; Department of Biology (Lab A-110), Faculty of Sciences, Universidad Autónoma de Madrid, C/Darwin 2, 28049, Madrid, Spain. Electronic address: paloma.fernandez@uam.es.
Jazyk: angličtina
Zdroj: Environmental pollution (Barking, Essex : 1987) [Environ Pollut] 2020 May; Vol. 260, pp. 114008. Date of Electronic Publication: 2020 Jan 21.
DOI: 10.1016/j.envpol.2020.114008
Abstrakt: Health and environmental risks regarding perfluorooctanoic acid, a well-known perfluorinated compound, are still a subject of great concern. Ubiquitous exposure and disparity of results make it difficult to determine the underlying mechanism of action, especially at the cellular level. This study proposes an experimental design to assess the reversibility of adverse effects after a one-time exposure to the compound, in comparison with other more conventional timings. Complementary endpoints including total protein content, neutral red uptake and MTT reduction tests along with division rates and microscopic observations were evaluated in HeLa cells. In addition, PFOA quantification inside the cells was performed. The cellular effects exerted after 24 h exposure to perfluorooctanoic acid are non-reversible after a 48 h recovery period. In addition, we describe for the first time the induction of plasma membrane blebbing and the activation of membrane repair mechanisms after recovery from non-cytotoxic treatments with the compound. This experimental design has provided relevant information regarding the toxicity of this perfluorinated compound, relating all the adverse effects detected to its interaction with the plasma membrane.
Competing Interests: Declaration of competing interest The authors declare no competing financial interest.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: